Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYROCKET: SBRT Followed by Atezolizumab and Tiragolumab in Metastatic NSCLC
NCT05034055Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Status: unknown.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05034055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034055.